PDCD1 and liver cancer: However, in the immunotherapy of liver cancer, the anti-PD-1 efficacy is as low as only 15–25%, which may be related to the special immune microenvironment of liver cancer, and the specific mechanism is still unclear (Pinero et al. 2020).